Ordering Recommendation

Diagnostic and predictive testing for multiple endocrine neoplasia type 2 (MEN2) syndrome caused by pathogenic variants in the RET gene.

New York DOH Approval Status

Testing is not New York state approved. Specimens from New York clients will be sent out to a New York state-approved laboratory.

Specimen Required

Patient Preparation
Collect

Lavender or pink (EDTA) or yellow (ACD solution A or B).
New York State Clients: Lavender (EDTA)

Specimen Preparation

Transport 3 mL whole blood. (Min: 2 mL)
New York State Clients: 5 mL (Min: 3 mL)

Storage/Transport Temperature

Refrigerated

Unacceptable Conditions

Serum or plasma; grossly hemolyzed or frozen specimens; saliva, buccal brush, or swab; FFPE tissue.

Remarks
Stability

Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: Unacceptable
New York State Clients: Ambient: 1 week; Refrigerated: 1 week; Frozen: 1 month

Methodology

Massively Parallel Sequencing

Performed

Varies

Reported

10-15 days

Reference Interval

By report

Interpretive Data

Refer to report.

Compliance Category

Laboratory Developed Test (LDT)

Note

Gene Tested: RET (NM_020975)

Hotline History

N/A

CPT Codes

81406

Components

Component Test Code* Component Chart Name LOINC
3004573 MEN2 Specimen 31208-2
3004574 MEN2 Interp
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • familial medullary thyroid cancer (FMTC)
  • MEN2A
  • MEN2B
Multiple Endocrine Neoplasia Type 2 (MEN2), RET Sequencing